Patients with Fabry disease have a significantly shorter life expectancy compared to the general population, often due to cardiac or renal complications of this rare disease. There are only 2 approved therapies for Fabry disease—enzyme replacement therapy and chaperone therapy. Management of Fabry disease and its complications is a rapidly evolving field with ongoing developments, from recent guideline recommendations to new data on approved therapies to promising clinical trials on investigational therapies. Timely and proper management is essential to slow progression and avert severe complications. Clinicians who care for patients with Fabry disease will receive focused and up-to-date education on managing this rare and complex disease. This activity will be delivered via an innovative online platform and led by faculty experts in Fabry disease using virtual small groups of learners to drive discussion and learning through assessments, self-study modules, group tasks, and live group discussions.

Click here to participate as a group member:
https://spire.gathered.com/curriculum/80